{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:15:02Z","timestamp":1773112502132,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 214274\/Z\/18\/Z"],"award-info":[{"award-number":["WT 214274\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MRC_MC_UU_12012.1"],"award-info":[{"award-number":["MRC_MC_UU_12012.1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI103629"],"award-info":[{"award-number":["R01AI103629"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009984","name":"ME Association","doi-asserted-by":"publisher","award":["PF8947_ME Association"],"award-info":[{"award-number":["PF8947_ME Association"]}],"id":[{"id":"10.13039\/100009984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a debilitating condition characterised by fatigue and post-exertional malaise. Its pathogenesis is poorly understood. GDF15 is a circulating protein secreted by cells in response to a variety of stressors. The receptor for GDF15 is expressed in the brain, where its activation results in a range of responses. Among the conditions in which circulating GDF15 levels are highly elevated are mitochondrial disorders, where early skeletal muscle fatigue is a key symptom. We hypothesised that GDF15 may represent a marker of cellular stress in ME\/CFS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>GDF15 was measured in serum from patients with ME\/CFS (n\u2009=\u2009150; 100 with mild\/moderate and 50 with severe symptoms), \u201chealthy volunteers\u201d (n\u2009=\u2009150) and a cohort of patients with multiple sclerosis (n\u2009=\u200950).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Circulating GDF15 remained stable in a subset of ME\/CFS patients when sampled on two occasions\u2009~\u20097\u00a0months (IQR 6.7\u20138.8) apart, 720\u00a0pg\/ml (95% CI 625\u2013816) vs 670\u00a0pg\/ml (95% CI 598\u2013796), <jats:italic>P\u2009<\/jats:italic>=\u20090.5. GDF15 levels were 491\u00a0pg\/ml in controls (95% CI 429\u2013553), 546\u00a0pg\/ml (95% CI 478\u2013614) in MS patients, 560\u00a0pg\/ml (95% CI 502\u2013617) in mild\/moderate ME\/CFS patients and 602\u00a0pg\/ml (95% CI 531\u2013674) in severely affected ME\/CFS patients. Accounting for potential confounders, severely affected ME\/CFS patients had GDF15 concentrations that were significantly increased compared to healthy controls (<jats:italic>P<\/jats:italic>\u2009=\u20090.01). GDF15 levels were positively correlated (<jats:italic>P\u2009<\/jats:italic>=\u20090.026) with fatigue scores in ME\/CFS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Severe ME\/CFS is associated with increased levels of GDF15, a circulating biomarker of cellular stress that appears which stable over several months.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-019-02153-6","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T11:03:18Z","timestamp":1575457398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Circulating levels of GDF15 in patients with myalgic encephalomyelitis\/chronic fatigue syndrome"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-8454","authenticated-orcid":false,"given":"A.","family":"Melvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Dockrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"O\u2019Rahilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Nacul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"1","key":"2153_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1741-7015-9-91","volume":"9","author":"LC Nacul","year":"2011","unstructured":"Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, Leite JC, Poland F, Howe A, Drachler ML. Prevalence of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med. 2011;9(1):91.","journal-title":"BMC Med"},{"key":"2153_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CLEP.S39876","volume":"5","author":"S Johnston","year":"2013","unstructured":"Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome\/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2153_CR3","first-page":"167","volume":"12","author":"IJ Bakken","year":"2014","unstructured":"Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, Magnus P. Two age peaks in the incidence of chronic fatigue syndrome\/myalgic encephalomyelitis: a population-based registry study from Norway 2008\u20132012. BMC Med. 2014;12(1):167.","journal-title":"BMC Med"},{"issue":"12","key":"2153_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-121-12-199412150-00009","volume":"121","author":"K Fukuda","year":"1994","unstructured":"Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953\u20139.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2153_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J092v11n01_02","volume":"11","author":"BM Carruthers","year":"2003","unstructured":"Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles AP, Sherkey JA. Myalgic encephalomyelitis\/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11(1):7\u2013115.","journal-title":"J Chronic Fatigue Syndr"},{"issue":"11","key":"2153_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2015.1346","volume":"313","author":"EW Clayton","year":"2015","unstructured":"Clayton EW. Beyond myalgic encephalomyelitis\/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313(11):1101\u20132.","journal-title":"JAMA"},{"key":"2153_CR7","volume-title":"ME\/CFS\/PVFS: an exploration of the key clinical issues","author":"DC Shepherd","year":"2018","unstructured":"Shepherd DC, Chaudhuri A. ME\/CFS\/PVFS: an exploration of the key clinical issues. Gawcott: ME Association; 2018."},{"issue":"2","key":"2153_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neucli.2017.02.002","volume":"47","author":"FK Mensah","year":"2017","unstructured":"Mensah FK, Bansal AS, Ford B, Cambridge G. Chronic fatigue syndrome and the immune system: where are we now? Clin Neurophysiol. 2017;47(2):131\u20138.","journal-title":"Clin Neurophysiol"},{"key":"2153_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3389\/fimmu.2019.00796","volume":"10","author":"JM Cliff","year":"2019","unstructured":"Cliff JM, King EC, Lee JS, Sep\u00falveda N, Wolf AS, Kingdon C, Bowman E, Dockrell HM, Nacul LC, Lacerda E, Riley E. Cellular immune function in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). Front Immunol. 2019;10:796.","journal-title":"Front Immunol"},{"key":"2153_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2497348","author":"G Rutherford","year":"2016","unstructured":"Rutherford G, Manning P, Newton JL. Understanding muscle dysfunction in chronic fatigue syndrome. J Aging Res. 2016. https:\/\/doi.org\/10.1155\/2016\/2497348.","journal-title":"J Aging Res."},{"issue":"2","key":"2153_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diagnostics9020041","volume":"9","author":"L Nacul","year":"2019","unstructured":"Nacul L, de Barros B, Kingdon CC, Cliff JM, Clark TG, Mudie K, Dockrell HM, Lacerda EM. Evidence of clinical pathology abnormalities in people with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) from an analytic cross-sectional study. Diagnostics. 2019;9(2):41.","journal-title":"Diagnostics."},{"issue":"3","key":"2153_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1042\/BST20170503","volume":"46","author":"C Tomas","year":"2018","unstructured":"Tomas C, Newton J. Metabolic abnormalities in chronic fatigue syndrome\/myalgic encephalomyelitis: a mini-review. Biochem Soc Trans. 2018;46(3):547\u201353.","journal-title":"Biochem Soc Trans"},{"issue":"10","key":"2153_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK, Foltz LA. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215.","journal-title":"Nat Med"},{"issue":"10","key":"2153_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD, Cavanaugh CR. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150.","journal-title":"Nat Med"},{"issue":"10","key":"2153_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkj\u00e6r SB, Wu X, Huang T, Hultman K, Paulsen SJ, Wang J. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017;23(10):1158.","journal-title":"Nat Med"},{"issue":"6","key":"2153_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cmet.2017.10.017","volume":"26","author":"S O\u2019Rahilly","year":"2017","unstructured":"O\u2019Rahilly S. GDF15\u2014from biomarker to allostatic hormone. Cell Metab. 2017;26(6):807\u20138.","journal-title":"Cell Metab"},{"issue":"3","key":"2153_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VW Tsai","year":"2018","unstructured":"Tsai VW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353\u201368.","journal-title":"Cell Metab"},{"issue":"9","key":"2153_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.molmet.2017.12.016","volume":"1","author":"M Kleinert","year":"2018","unstructured":"Kleinert M, Clemmensen C, Sj\u00f8berg KA, Carl CS, Jeppesen JF, Wojtaszewski JF, Kiens B, Richter EA. Exercise increases circulating GDF15 in humans. Mol Metab. 2018;1(9):187\u201391.","journal-title":"Mol Metab"},{"issue":"4","key":"2153_CR19","doi-asserted-by":"publisher","first-page":"e34868","DOI":"10.1371\/journal.pone.0034868","volume":"7","author":"L Macia","year":"2012","unstructured":"Macia L, Tsai VW, Nguyen AD, Johnen H, Kuffner T, Shi YC, Lin S, Herzog H, Brown DA, Breit SN, Sainsbury A. Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS ONE. 2012;7(4):e34868.","journal-title":"PLoS ONE"},{"issue":"2","key":"2153_CR20","doi-asserted-by":"publisher","first-page":"e55174","DOI":"10.1371\/journal.pone.0055174","volume":"8","author":"VW Tsai","year":"2013","unstructured":"Tsai VW, Macia L, Johnen H, Kuffner T, Manadhar R, J\u00f8rgensen SB, Lee-Ng KK, Zhang HP, Wu L, Marquis CP, Jiang L. TGF-b superfamily cytokine MIC-1\/GDF15 is a physiological appetite and body weight regulator. PLoS ONE. 2013;8(2):e55174.","journal-title":"PLoS ONE"},{"key":"2153_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fneur.2018.01026","volume":"9","author":"EM Lacerda","year":"2018","unstructured":"Lacerda EM, Mudie K, Kingdon CC, Butterworth JD, O\u2019Boyle S, Nacul L. The UK ME\/CFS Biobank: a disease-specific biobank for advancing clinical research into myalgic encephalomyelitis\/chronic fatigue syndrome. Front Neurol. 2018;9:1026.","journal-title":"Front Neurol"},{"key":"2153_CR22","doi-asserted-by":"publisher","DOI":"10.5334\/ojb.28","author":"EM Lacerda","year":"2017","unstructured":"Lacerda EM, Bowman EW, Cliff JM, Kingdon CC, King EC, Lee JS, Clark TG, Dockrell HM, Riley EM, Curran H, Nacul L. The UK ME\/CFS biobank for biomedical research on myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and multiple sclerosis. Open J Bioresour. 2017. https:\/\/doi.org\/10.5334\/ojb.28.","journal-title":"Open J Bioresour"},{"key":"2153_CR23","unstructured":"UK NCGC. Modifiable risk factors for relapse or progression of MS. In Multiple sclerosis: management of multiple sclerosis in primary and secondary care 2014 Oct. National Institute for Health and Care Excellence (UK)."},{"key":"2153_CR24","volume-title":"User\u2019s manual for the SF-36v2 health survey","author":"JE Ware","year":"2007","unstructured":"Ware JE. User\u2019s manual for the SF-36v2 health survey. Quality Metric: Lincoln; 2007."},{"issue":"7889","key":"2153_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(74)90884-8","volume":"304","author":"EC Huskisson","year":"1974","unstructured":"Huskisson EC. Measurement of pain. Lancet. 1974;304(7889):1127\u201331.","journal-title":"Lancet."},{"issue":"10","key":"2153_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121\u20133.","journal-title":"Arch Neurol"},{"issue":"21","key":"2153_CR27","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u03b2 superfamily. Proc Natl Acad Sci. 1997;94(21):11514\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"2153_CR28","first-page":"4781","volume":"85","author":"AG Moore","year":"2000","unstructured":"Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, Russell PK, Salamonsen LA, Wallace EM, Breit SN. The transforming growth factor-\u03b2 superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab. 2000;85(12):4781\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2153_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel S, Alvarez-Guaita A, Melvin A, Rimmington D, Dattilo A, Miedzybrodzka EL, Cimino I, Maurin AC, Roberts GP, Meek CL, Virtue S. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 2019;29(3):707\u201318.","journal-title":"Cell Metab"},{"issue":"1","key":"2153_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1083\/jcb.201607110","volume":"216","author":"HK Chung","year":"2017","unstructured":"Chung HK, Ryu D, Kim KS, Chang JY, Kim YK, Yi HS, Kang SG, Choi MJ, Lee SE, Jung SB, Ryu MJ. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol. 2017;216(1):149\u201365.","journal-title":"J Cell Biol"},{"issue":"10","key":"2153_CR31","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374\u201395.","journal-title":"EMBO Rep"},{"issue":"1","key":"2153_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2164-15-91","volume":"15","author":"SG Kalko","year":"2014","unstructured":"Kalko SG, Paco S, Jou C, Rodr\u00edguez MA, Meznaric M, Rogac M, Jekovec-Vrhovsek M, Sciacco M, Moggio M, Fagiolari G, De Paepe B. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics. 2014;15(1):91.","journal-title":"BMC Genomics."},{"issue":"20","key":"2153_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mito.2014.10.006","volume":"1","author":"Y Fujita","year":"2015","unstructured":"Fujita Y, Ito M, Kojima T, Yatsuga S, Koga Y, Tanaka M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion. 2015;1(20):34\u201342.","journal-title":"Mitochondrion"},{"issue":"5","key":"2153_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","volume":"78","author":"S Yatsuga","year":"2015","unstructured":"Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T, Ito M, Tanaka M, Saiki R, Koga Y. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015;78(5):814\u201323.","journal-title":"Ann Neurol"},{"issue":"2","key":"2153_CR35","doi-asserted-by":"publisher","first-page":"e0148709","DOI":"10.1371\/journal.pone.0148709","volume":"11","author":"R Montero","year":"2016","unstructured":"Montero R, Yubero D, Villarroya J, Henares D, Jou C, Rodr\u00edguez MA, Ramos F, Nascimento A, Ortez CI, Campistol J, Perez-Due\u00f1as B. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS ONE. 2016;11(2):e0148709.","journal-title":"PLoS ONE"},{"issue":"6","key":"2153_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10974-008-9128-y","volume":"28","author":"S Fulle","year":"2007","unstructured":"Fulle S, Pietrangelo T, Mancinelli R, Saggini R, Fano G. Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis. J Muscle Res Cell Motil. 2007;28(6):355\u201362.","journal-title":"J Muscle Res Cell Motil"},{"issue":"10","key":"2153_CR37","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1007\/s12035-016-0283-7","volume":"54","author":"X Ji","year":"2017","unstructured":"Ji X, Zhao L, Ji K, Zhao Y, Li W, Zhang R, Hou Y, Lu J, Yan C. Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases. Mol Neurobiol. 2017;54(10):8110\u20136.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2153_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12881-017-0387-6","volume":"18","author":"EM Schoeman","year":"2017","unstructured":"Schoeman EM, Van Der Westhuizen FH, Erasmus E, Van Dyk E, Knowles CV, Al-Ali S, Ng WF, Taylor RW, Newton JL, Elson JL. Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome. BMC Med Genet. 2017;18(1):29.","journal-title":"BMC Med Genet"},{"key":"2153_CR39","unstructured":"GTEx Portal. https:\/\/gtexportal.org\/home\/gene\/GDF15. Accessed 28 Sept 2019."},{"key":"2153_CR40","doi-asserted-by":"publisher","first-page":"205873841882040","DOI":"10.1177\/2058738418820402","volume":"33","author":"E Sweetman","year":"2019","unstructured":"Sweetman E, Ryan M, Edgar C, MacKay A, Vallings R, Tate W. Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis\/chronic fatigue syndrome. Int J Immunopathol Pharmacol. 2019;33:2058738418820402.","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-02153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-02153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-02153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T01:34:11Z","timestamp":1606959251000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-02153-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-02153-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"6 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the study was obtained from the MREC and LSHTM Ethics Committee (REC reference 16\/WA\/0289 and LSHTM ethics committee 6123). Informed consent was obtained from all study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}